INTRODUCTION
============

Endoscopic submucosal dissection (ESD) has been recognized as a standard treatment for selected cases of early gastric cancer in Korea.[@b1-gnl-13-515],[@b2-gnl-13-515] Compared to surgery, ESD has advantages in that it can preserve the stomach with relatively non-invasive technique. In addition, ESD can promote high rates of *en bloc* resection which provides complete histologic evaluation of totally excised specimens even if lesions are massive.[@b3-gnl-13-515] However, significant ESD-related complications including bleeding and perforation could occur.[@b2-gnl-13-515],[@b4-gnl-13-515],[@b5-gnl-13-515]

Perforation is a major complication of ESD. The incidence of ESD-related perforation has been reported to be about 1.2% to 6.1%.[@b6-gnl-13-515]--[@b8-gnl-13-515] Recently, it has been reported that most perforations caused by ESD could be treated with immediate endoscopic clipping and without additional surgery.[@b9-gnl-13-515] However, the clinical course after perforation must be taken into consideration, including peritoneal seeding.[@b10-gnl-13-515],[@b11-gnl-13-515] The possibility of disseminating cancer cells into the peritoneal cavity is a potential drawback associated with minimal invasive procedure such as ESD.

Whether perforation associated with endoscopic resection causes peritoneal seeding during ESD has been controversial.[@b10-gnl-13-515],[@b12-gnl-13-515] Therefore, the objective of this study was to investigate long-term clinical outcomes including peritoneal seeding and overall survival rate following gastric perforation during ESD.

MATERIALS AND METHODS
=====================

1. Study population
-------------------

Between January 2002 and March 2015, 556 patients who were diagnosed with early gastric cancer underwent ESD at Incheon St. Mary's Hospital, The Catholic University of Korea. Among them, 34 patients (6.1%) experienced gastric perforation during ESD. Clinicopathological data of these 34 patients were reviewed. The Institutional Review Board of The Catholic University of Korea approved this study. The informed consent was waived due to retrospective design.

2. ESD procedure and endoscopic clip technique
----------------------------------------------

All ESD procedures were performed by two expert endoscopists (B.W.K. and J.S.K.). After patients were moderately sedated with midazolam and propofol, ESD was performed. A video endoscope with or without a water-jet function (GIF-HQ290, GIF-Q260, GIF-H260; Olympus, Tokyo, Japan) was routinely used. A disposable distal transparent cap (D-201-11804; Olympus) was mounted on the tip of the endoscope in all cases. Carbon dioxide or air was used for the insufflation. To identify target lesion, chromoendoscopy with indigo carmine solution or narrow band imaging with or without magnification was used. Following circumferential marking (using argon plasma coagulation), a mixture of indigo carmine, diluted epinephrine (1:200,000), and 10% glycerol (Cerol; JW Pharmaceutical Co., Seoul, Korea) was used to inject submucosa as marked. Epinephrine (1:1,000, total epinephrine 1 mg) was mixed in a 200-mL container of glycerol, and 8 mL of the solution was drawn into 10-mL disposable syringe to use for gastric lesion. After injection, an initial incision was made outside the marks with a dual knife or a hook knife. A knife was inserted into the initial incision, and electrosurgical current was applied with the use of an electrosurgical unit (VIO300D; Endocut I mode, effect 2; ERBE, Tubingen, Germany) to complete the circumferential mucosal incision around the lesion and submucosal dissection. The ESD procedure was performed mainly with a dual knife (KD-650Q; Olympus), an IT-knife 2 (KD-610L; Olympus), or a hook knife (KD-620LR; Olympus). Hemostatic forceps (Coagrasper, FD-410LR; Olympus) with a soft coagulation mode (VIO300D; Soft coag mode, effect 4; ERBE) were used to control bleeding during the procedure. In the case of macroperforation, perforation site was closed with endoclips (EZ clip; Olympus) using single closure methods. Even if there was no macroperforation, preventive clipping was performed when lesion was considered to be dissected deeply.

3. Definition
-------------

Perforation was classified into two types; macroperforation was defined as a gross defect noted during endoscopic procedure; microperforation was identified as a pneumoperitoneum by radiological evidence after the procedure without gross defect during the procedure. We defined curative resection according to the Japanese gastric cancer treatment guidelines as follows: *en bloc* resection, negative horizontal and vertical margins, no lymphovascular invasion, and one of the following: (1) tumor size ≤2 cm, differentiated type, mucosa, and ulcer (−); (2) tumor size \>2 cm, differentiated type, mucosa, and ulcer (−); (3) tumor size ≤3 cm, differentiated type, mucosa, and ulcer (+); (4) tumor size ≤2 cm, undifferentiated type, mucosa, and ulcer (−); or (5) tumor size ≤3 cm, differentiated type, and submucosal layer 1 (SM1).[@b13-gnl-13-515] In our study, the peritoneal seeding was defined as the direct spreading of cancer cells due to perforation during endoscopic resection.

4. Follow-up
------------

After ESD, follow-up consisted of endoscopic examination at three months and biannually thereafter for 2 years followed by annual follow-up to check local or metachronous recurrence. Annual abdominal computed tomography (CT) was performed to determine extragastric recurrence. We defined "follow-up loss" as the follow-up period of less than 1 year.

5. Statistical analysis
-----------------------

Between-group comparisons of clinical characteristics were conducted using the chi-square or Fisher exact test, and applying the Student t-test for non-categorical variables. Clinicopathologic factors associated with cancer recurrence were evaluated by logistic regression analysis. The Kaplan-Meier method was used to determine cumulative survival rate and the log-rank test was used to analyze differences in survival curve. The descriptive statistics were used for continuous variables. Accepted significance level was set at p-value \<0.05. All statistical analyses were performed using SPSS version 20.0 for Windows (IBM Corp., Armonk, NY, USA).

RESULTS
=======

1. Clinicopathologic characteristics and clinical outcome between non-perforation and perforation groups
--------------------------------------------------------------------------------------------------------

Among 556 patients who were diagnosed with early gastric cancer and underwent ESD at Incheon St. Mary's Hospital, 17 patients were excluded due to follow-up loss. Median follow-up was 51.9±27.5 months (range, 12.2 to 166.1 months). Age, sex, tumor size, macroscopic type, histology, lymphovascular invasion, curative resection, and cancer recurrence did not differ between non-perforation and perforation groups ([Table 1](#t1-gnl-13-515){ref-type="table"}). However, tumor location (middle and upper location) and depth of invasion (SM2 invasion) showed statistically significant associations with perforation. In perforation group, macroperforation occurred in 17 cases during ESD while microperforation occurred in the remaining 17 cases. Perforation during ESD was treated immediately by endoscopic clipping for 27 patients. One patient who suffered from panperitonitis after ESD subsequently underwent emergency surgery (wedge resection and primary repair). The remaining six patients received conservative medical treatment without endoscopic clipping or emergency surgery.

2. Clinical outcome of patients with perforations during ESD
------------------------------------------------------------

Clinical outcomes of patients with macro- and micro- perforation are shown in [Fig. 1](#f1-gnl-13-515){ref-type="fig"}. Of 34 patients, seven patients had non-curative resection while one patient had peritoneal seeding during follow-up. [Table 2](#t2-gnl-13-515){ref-type="table"} shows the characteristics of these seven patients with non-curative resection. Three patients refused additional surgery while three patients underwent additional surgery (gastrectomy and lymph node dissection). One patient (patient 5) who suffered from panperitonitis after ESD subsequently underwent emergency surgery (wedge resection and simple closure without lymph node dissection). The final pathology of resected specimen revealed submucosal invasion with depth of 4,000 μm. The patient was recommended to undergo additional surgery including lymph node dissection. However, the patient refused our suggestion at that time. Two years later, the patient showed massive retroperitoneal metastatic lymphadenopathy and tumor seeding with neck and brain metastasis on follow-up CT.

Univariate and multivariate analyses were performed to identify factors associated with cancer recurrence ([Tables 3](#t3-gnl-13-515){ref-type="table"} and [4](#t4-gnl-13-515){ref-type="table"}). Multivariate analysis showed that tumor size and achievement of curative resection were related to cancer recurrence ([Table 4](#t4-gnl-13-515){ref-type="table"}). Perforation was not associated with cancer recurrence.

3. Cumulative survival rates between perforation and non-perforation groups
---------------------------------------------------------------------------

We excluded patients who underwent additional surgery after non-curative resection (non-perforation group, n=43 and perforation group, n=4). The Kaplan-Meier analysis indicated that patients with perforation had similar cumulative survival rate compared to those with non-perforation in our cohort ([Fig. 2](#f2-gnl-13-515){ref-type="fig"}). There was no mortality associated with perforation.

DISCUSSION
==========

The overall frequency of perforation found in our study was 6.1% (microperforation, 50% and macroperforation, 50%), consistent with previous reports.[@b6-gnl-13-515]--[@b8-gnl-13-515] Overall cumulative survival rate did not differ between perforation and non-perforation groups with median follow up of 51.9±27.5 months. There was no evidence of peritoneal seeding after a perforation associated with ESD in this study.

Perforation is a major complication of ESD. It is related to significant morbidity and mortality. In some cases, emergency surgery is required and the risk of peritoneal seeding should be considered.[@b7-gnl-13-515],[@b9-gnl-13-515] Peritoneal seeding following fine needle biopsy for hepatocellular carcinoma and port-site seeding after laparoscopic surgery have been reported.[@b14-gnl-13-515],[@b15-gnl-13-515] Theoretically, perforation of the gastric wall in a lesion containing cancer cells during ESD may lead to peritoneal seeding.

Two studies have reported the risk of peritoneal seeding after perforation during gastric endoscopic resection to date. In a retrospective study of 90 patients with perforation after gastric endoscopic resection, there was no peritoneal seeding.[@b12-gnl-13-515] A recent retrospective study has reported peritoneal seeding occurring in two of 22 patients with perforation following gastric endoscopic resection.[@b10-gnl-13-515] In this previous study, the ESD specimen of one patient had pathologic vertical margin positive and deep SM invasion. Another patient with mucosal cancer underwent emergency surgery for acute peritonitis. However, several clinicopathological characteristics (e.g., curative resection, depth of invasion, type of additive operation, etc.) of these two patients could not be verified. A case of peritoneal seeding after perforation during ESD has also been reported.[@b11-gnl-13-515] In this case, however, cancer cell existed in muscularis propria layer in the ESD specimen. Therefore, it is unclear whether peritoneal seeding and perforation during ESD are directly linked. Furthermore, previous studies have several limitations such as relatively short-term follow-up period and lack of clinicopathological characteristics (e.g., curative resection, depth of invasion, survival rate, etc.).

To overcome such limitations, the present study was conducted with relatively long-term follow-up period. In addition, several clinicopathological factors including cumulative survival rate were validated. Our results revealed that gastric perforation during ESD did not lead to peritoneal dissemination, even in the long term. Cumulative survival rates did not differ between perforation and non-perforation groups either. In the perforation group, one patient displayed massive retroperitoneal metastatic lymphadenopathy and tumor seeding with neck and brain metastasis on follow-up CT. Although peritoneal recurrence occurred in this patient, it might not be related to perforation during ESD. The patient strongly refused additional surgery including lymph node dissection. Several studies have reported that lymph node metastasis can occur in 3.4% to 9.3% of patients after undergoing additive surgery following non-curative resection.[@b16-gnl-13-515]--[@b19-gnl-13-515] Thus, it is reasonable to consider the case as a multiple organ metastasis from perilesional lymph node metastasis. Although the lack of peritoneal sampling was a major limitation of the present study, this case was not peritoneal seeding due to perforation.

In our study, the perforation group and the non-perforation group showed similar cumulative survival rates even in the long term. In addition, perforation was not associated with cancer recurrence. Our results suggest that perforation associated with ESD procedure could be successfully managed using non-surgical method (e.g., endoscopic clipping and conservative care). In addition, if resected lesion meets "curative resection," periodic follow-up could be allowed regardless of perforation.

Our study has several limitations. First, this was a retrospective study which restricted our ability to control certain aspects of the study. Second, we did not perform peritoneal lavage in patients with perforation. Third, the number of perforations was relatively small due to low rates of perforation. Nevertheless, our study has the strength of long-term follow up for clinical courses of patients with perforation.

In conclusion, results of this study demonstrated that perforation during ESD was not accompanied by worse clinical outcome such as peritoneal seeding and cumulative survival rate. Therefore, periodic follow-up is possible if curative resection is achieved regardless of perforation during ESD.

See editorial on page 481.
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###### 

Clinicopathologic Characteristics and Clinical Outcomes between the Non-perforation and Perforation Groups

  Characteristics            Non-perforation group (n=505)   Perforation group (n=34)   p-value
  -------------------------- ------------------------------- -------------------------- ---------
  Age, yr                    66.3±10.1                       64.3±8.2                   0.230
  Sex, male:female           358:147                         27:7                       0.287
  Tumor location                                                                        \<0.001
   Upper                     29 (5.7)                        6 (17.6)                   
   Middle                    108 (21.4)                      19 (55.9)                  
   Lower                     368 (72.9)                      9 (26.5)                   
  Tumor size, mm                                                                        0.516
   \<20                      288 (57.0)                      16 (47.1)                  
   20--30                    149 (29.5)                      12 (35.3)                  
   \>30                      68 (13.5)                       6 (17.6)                   
  Macroscopic type                                                                      0.405
   Elevated                  196 (38.8)                      17 (50.0)                  
   Flat                      143 (28.3)                      7 (20.6)                   
   Depressed                 166 (32.9)                      10 (29.4)                  
  Histology                                                                             0.481
   Differentiated            457 (90.5)                      32 (94.1)                  
   Undifferentiated          48 (9.5)                        2 (5.9)                    
  Depth of invasion                                                                     
   Mucosa                    430 (85.2)                      25 (73.5)                  0.010
   SM1 (\<500 μm)            42 (8.3)                        2 (5.9)                    
   SM2 (≥500 μm)             33 (6.5)                        7 (20.6)                   
  Lymphovascular invasion                                                               0.350
   Absent                    469 (92.9)                      33 (97.1)                  
   Present                   36 (7.1)                        1 (2.9)                    
  Curative resection                                                                    0.287
   Yes                       358 (70.9)                      27 (79.4)                  
   No                        147 (29.1)                      7 (20.6)                   
  Additive surgery           50 (9.9)                        4 (11.8)                   0.726
  Recurrence                 29 (5.7)                        1 (2.9)                    0.490
   Local recurrence          28                              0                          
   Extragastric recurrence   1                               1                          
  Perforation                \-                                                         \-
   Macroperforation                                          17 (50.0)                  
   Microperforation                                          17 (50.0)                  
  Treatment of perforation   \-                                                         \-
   Endoscopic clipping                                       27 (79.4)                  
   Emergency surgery                                         1 (2.9)                    
   Conservative care                                         6 (17.7)                   

Data are presented as mean±SD or number (%).

SM, submucosa.

###### 

Characteristics of Patients with Non-curative Endoscopic Resection (n=7)

  Variable                    Patient 1           Patient 2             Patient 3                                           Patient 4             Patient 5                                                  Patient 6                                           Patient 7
  --------------------------- ------------------- --------------------- --------------------------------------------------- --------------------- ---------------------------------------------------------- --------------------------------------------------- ---------------------------------------------------
  Sex                         Male                Female                Male                                                Female                Male                                                       Male                                                Male
  Age, yr                     56                  49                    64                                                  62                    71                                                         62                                                  64
  Tumor location              Middle              Lower                 Middle                                              Upper                 Middle                                                     Middle                                              Middle
  Tumor size, mm              15                  15                    5                                                   20                    24                                                         32                                                  32
  Histology                   Differentiated      Differentiated        Differentiated                                      Differentiated        Differentiated                                             Differentiated                                      Undifferentiated
  Non-curative factor         SM2 invasion        LM positive           SM2 invasion                                        SM2 invasion          SM2 invasion                                               LM positive                                         SM2 invasion
  Resection type              *En*-*bloc*         *En*-*bloc*           *En*-*bloc*                                         *En*-*bloc*           *En*-*bloc*                                                *En*-*bloc*                                         *En*-*bloc*
  Perforation                 Microperforation    Microperforation      Microperforation                                    Macroperforation      Macroperforation                                           Macroperforation                                    Macroperforation
  Management of perforation   Conservative care   Endoscopic clipping   Endoscopic clipping                                 Endoscopic clipping   Emergency operation (wedge resection and primary repair)   Endoscopic clipping                                 Endoscopic clipping
  Treatment after NCR         Refusing surgery    Refusing surgery      Additive surgery (gastrectomy with LN dissection)   Refusing surgery      Emergency operation (wedge resection and primary repair)   Additive surgery (gastrectomy with LN dissection)   Additive surgery (gastrectomy with LN dissection)
  Follow-up, mo               98                  59                    49                                                  84                    28                                                         51                                                  36
  Recurrence                  No                  No                    No                                                  No                    Yes                                                        No                                                  No
  Peritoneal seeding          No                  No                    No                                                  No                    Yes                                                        No                                                  No
  Survival                    Yes                 Yes                   Yes                                                 Yes                   No                                                         Yes                                                 Yes

SM, submucosa; LM, lateral margin; NCR, non-curative resection; LN, lymph node.

###### 

Univariate Analysis of Clinicopathologic Characteristics Associated with Cancer Recurrence

  Characteristic            No recurrence (n=509)   Recurrence (n=30)   p-value
  ------------------------- ----------------------- ------------------- ---------
  Age, yr                                                               0.143
   \<65                     222 (43.6)              9 (30.0)            
   ≥65                      287 (56.4)              21 (70.0)           
  Sex, male:female          363:146                 22:8                0.812
  Tumor location                                                        0.083
   Upper                    31 (6.1)                4 (13.3)            
   Middle                   124 (24.4)              3 (10.0)            
   Lower                    354 (69.5)              23 (76.7)           
  Tumor size, mm                                                        \<0.001
   \<20                     301 (59.1)              3 (10.0)            
   20--30                   143 (28.1)              18 (60.0)           
   \>30                     65 (12.8)               9 (30.0)            
  Macroscopic type                                                      0.197
   Elevated                 201 (39.5)              12 (40.0)           
   Flat                     138 (27.1)              12 (40.0)           
   Depressed                170 (33.4)              6 (20.0)            
  Histology                                                             0.431
   Differentiated           463 (91.0)              26 (86.7)           
   Undifferentiated         46 (9.0)                4 (13.3)            
  Depth of invasion                                                     
   Mucosa                   431 (84.6)              24 (80.0)           0.783
   SM1 (\<500 μm)           41 (8.1)                3 (10.0)            
   SM2 (≥500 μm)            37 (7.3)                3 (10.0)            
  Lymphovascular invasion                                               0.431
   Absent                   473 (92.9)              29 (96.7)           
   Present                  36 (7.1)                1 (3.3)             
  Curative resection                                                    \<0.001
   Yes                      374 (73.5)              11 (36.7)           
   No                       135 (26.5)              19 (63.3)           
  Perforation                                                           
   Yes                      33 (6.5)                1 (3.3)             0.490
   No                       476 (93.5)              29 (96.7)           

Data are presented as number (%).

SM, submucosa.

###### 

Multivariate Analysis of Clinicopathologic Characteristics Associated with Cancer Recurrence

  Characteristic       OR (95% CI)          p-value
  -------------------- -------------------- ---------
  Tumor size, mm                            
   \<20                Reference            \-
   20--30              9.97 (2.83--35.07)   \<0.001
   \>30                8.17 (2.01--33.19)   0.003
  Curative resection                        
   Yes                 Reference            \-
   No                  2.73 (1.20--6.25)    0.017

OR, odds ratio; CI, confidence interval.
